IP Library Granted Patent US 12,606,549
Granted Patent B2
US 12,606,549 · App. 18/254,405 · Granted Apr 21, 2026

Anticholinergic agents

Inventors: Yusheng Xiong (Zhuhai, CN); Hongping Guan (Zhuhai, CN)
Assignee: REZUBIO PHARMACEUTICALS CO., LTD
C07D413/12C07D207/08C07D207/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,606,549
App. No.
18/254,405
Granted
Apr 21, 2026
Kind
B2
Abstract

Compounds shown in Formula (I), pharmaceutical compositions, and methods of using related to muscarinic acetylcholine receptors. The compounds herein are typically muscarinic acetylcholine receptor antagonists, such as M 3 antagonists, which can be used for treating a variety of disorders, conditions or diseases such as hyperhidrosis.

Claims (34)

1 . A salt having Formula I:

wherein:

X − is a counterion;

R 1 is hydrogen;

L 1 is null, C 1-4 alkylene, or C 1-4 heteroalkylene;

R 2 is C 3-8 carbocyclyl, 4-8 membered heterocyclyl, phenyl, or 5-10 membered heteroaryl, each of which is optionally substituted;

R 3 and R 4 are each independently hydrogen or C 1-6 alkyl; and

j is 0, 1 or 2.

2 . The salt of claim 1 , which has a formula according to Formula I-1 or Formula I-2:

3 . The salt of claim 1 , wherein L 1 is null or a C 1-4 alkylene.

4 . The salt of claim 1 , wherein L 1 is CH 2 .

5 . The salt of claim 1 , wherein R 2 is C 3-6 cycloalkyl, which is optionally substituted with one or more substituents independently selected from F, OH, R A , and OR A , wherein R A at each occurrence is independently a C 1-4 alkyl or C 3-6 cycloalkyl, which is optionally substituted with one or more substituents independently selected from F, OH, C 1-4 alkyl, fluorine-substituted C 1-4 alkyl, C 1-4 alkoxy, and fluorine-substituted C 1-4 alkoxy; (ii) C 4-7 cycloalkenyl, such as cyclopentenyl, which is optionally substituted with one or more substituents independently selected from F, OH, R A , and OR A , wherein R A at each occurrence is independently a C 1-4 alkyl or C 3-6 cycloalkyl, which is optionally substituted with one or more substituents independently selected from F, OH, C 1-4 alkyl, fluorine-substituted C 1-4 alkyl, C 1-4 alkoxy, and fluorine-substituted C 1-4 alkoxy; (v) (iii) phenyl, which is optionally substituted with one or more substituents independently selected from F, Cl, OH, C 1-4 alkyl, fluorine-substituted C 1-4 alkyl, C 1-4 alkoxy, and fluorine-substituted C 1-4 alkoxy; (iv) a 5-membered heteroaryl having 1-3 ring heteroatoms independently selected from N, O, and S, which is optionally substituted with one or more substituents independently selected from F, Cl, OH, C 1-4 alkyl, fluorine-substituted C 1-4 alkyl, C 1-4 alkoxy, and fluorine-substituted C 1-4 alkoxy; or (v) a 6-membered heteroaryl having 1-2 ring heteroatoms independently selected from N, O, and S, which is optionally substituted with one or more substituents independently selected from F, Cl, OH, C 1-4 alkyl, fluorine-substituted C 1-4 alkyl, C 1-4 alkoxy, and fluorine-substituted C 1-4 alkoxy.

6 . The salt of claim 1 , wherein R 3 is methyl.

7 . The salt of claim 1 , wherein R 4 is methyl.

8 . The salt of claim 1 , wherein j is 1.

9 . The salt of claim 1 , wherein X − is a pharmaceutically acceptable counterion.

10 . A salt selected from those shown in Table 1 or 2, wherein X − is a pharmaceutically acceptable counterion:

TABLE 1

TABLE 2

11 . A pharmaceutical composition comprising the salt of claim 9 and optionally a pharmaceutically acceptable carrier.

12 . The pharmaceutical composition of claim 11 , which is formulated for topical administration.

13 . The pharmaceutical composition of claim 11 , which is in the form of a topical solution, cream, ointment, mousse, gel, lotion, or powder.

14 . A method of treating hyperhidrosis, reducing drooling, reducing secretions in stomach or airway, protecting heart and nervous system, treating chronic obstructive pulmonary disease, inducing pupil dilation, or treating abdominal pain in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the salt of claim 9 .

15 . The method of claim 14 , wherein the method is for treating hyperhidrosis, and the administering is a topical administration.

16 . A compound having Formula II, or a salt thereof:

wherein:

R 1 is hydrogen;

L 1 is null, C 1-4 alkylene, or C 1-4 heteroalkylene;

R 2 is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 carbocyclyl, 4-8 membered heterocyclyl, phenyl, or 5-10 membered heteroaryl, each of which is optionally substituted;

R 3 is hydrogen or C 1-6 alkyl; and

j is 0, 1 or 2.

17 . The compound of claim 16 , or a salt thereof, which has a formula according to Formula II-1 or Formula II-2:

18 . The salt of claim 5 , wherein L 1 is CH 2 .

19 . The salt of claim 18 , wherein j is 1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2026
From: GUAN, HONGPING; XIONG, YUSHENG
To: REZUBIO PHARMACEUTICALS CO., LTD
Reel/Frame 074139/0358 →
Priority Claims (1)
WO PCT/CN2020/131836 · Nov 26, 2020 · international
Continuity (1)
Related Publication 20240002372A1 · Jan 4, 2024
References Cited (19)
US 2956062A · Lunsford et al. · 1960 [cited by applicant]
US 3301869A · Lunsford et al. · 1967 [cited by applicant]
US 7504432B2 · Ogino · 2009 [cited by examiner]
US 10100012B2 · Dugar et al. · 2018 [cited by applicant]
US 11414406B2 · Lindsley et al. · 2022 [cited by applicant]
US 20020173536A1 · Noe et al. · 2002 [cited by applicant]
US 20090028873A1 · Gant · 2009 [cited by examiner]
US 20180186735A1 · Shaw et al. · 2018 [cited by applicant]
CN 106659697 · 2017 [cited by applicant]
CN 111788182 · 2020 [cited by applicant]
JP 2017522366 · 2017 [cited by applicant]
Di, Int J Pharm, vol. 297, 2005, 110-119. (Year: 2005). [cited by examiner]
Hill, Anal Chem, 200, vol. 0, 5574-5582. (Year: 2008). [cited by examiner]
Wu, Pyrrolidines I, vol. 26, 1961, 1519-1524. (Year: 1961). [cited by examiner]
Wu, Pyrrolidines II, 1524-1528, vol. 26, 1960. (Year: 1960). [cited by examiner]
Yamashita ey al., “Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity”, Bioorganic & Medicinal Chemistry, 2019, pp. 3… [cited by applicant]
Registry Copyright 2022 ACS on STN, CAS “1834577-91-1”, STN, pp. 1-73. [cited by applicant]
Doyle et al., “Pharmacodynamic Compounds. Part I. Some. Antispasmodics derived from Substituted 2-Pyrrolidinylallcccnols”, Jan. 1, 1958, Downloaded by State Intellectual Property Office of P.R.C. on Apr. 7, 2024, pp. 44… [cited by applicant]
Ryan et al., “The Synthesis and Anticholinergic Activity of Ester and Amiddler-ivatives of 2-Substituted Piperidines”, Derivatives of 2-Substituted Piperidines, May 1961, vol. 26, pp. 1547-1550. [cited by applicant]